Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2009

View Archived Issues

NuPathe reports phase III results for Zelrix transdermal patch for migraine

FDA Advisory Committee recommends GE Healthcare's DaTSCAN

Ikaria to in-license worldwide rights to investigational fibrin-derived peptides

Javelin reports phase III results for intranasal ketamine in pain

Genmab presents preliminary topline results for Arzerra in CLL

Nycomed and Forest to collaborate on roflumilast for COPD

In vivo pharmacokinetics and metabolism data on afobazole presented at EACPT

Squalene synthase inhibitors display preclinical anti-atherosclerotic activity in recent study

Dako collaborates with Genentech on diagnostic tests for gastric cancer

PARP inhibitor PJ-34 reduces tPA-induced intracerebral hemorrhage in ischemic mice

Novel VEGF inhibitor NP-184 displays anti-angiogenic activity in preclinical study

Antithrombotic effects and improved safety shown by AVE-5026 in animal models

Wyeth receives notice from FDA for extended Prevnar 13 action date

Preliminary phase I and I/II data suggest safety and clinical activity of IMGN-901 in SCLC

Multaq approved in Canada for atrial fibrillation

Opexa enters into stem cell agreement with Novartis

Forest and AstraZeneca to codevelop and commercialize ceftaroline

Abbott discloses histamine H3 receptor ligands for the treatment of ADHD

Kissei describes COMT inhibitors for the treatment of Parkinson's disease

S1P1 receptor agonists in development at GSK

Sanofi-aventis synthesizes P2Y12 receptor antagonists useful in antiplatelet therapy

Novel vitamin D3 derivatives reported for the treatment of psoriasis

Shanghai Hengrui claims DDP IV inhibitors for the treatment of diabetes

ALK5 inhibitors in early development at Novartis for the treatment of PAH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...